Cargando…
Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer
Most breast cancers at an advanced stage exhibit an aggressive nature, and there is a lack of effective anticancer options. Herein, the development of patient‐derived organoids (PDOs) is described as a real‐time platform to explore the feasibility of tailored treatment for refractory breast cancers....
Autores principales: | Chen, Ping, Zhang, Xu, Ding, Renbo, Yang, Linglin, Lyu, Xueying, Zeng, Jianming, Lei, Josh Haipeng, Wang, Lijian, Bi, Jiong, Shao, Nan, Shu, Ditian, Wu, Bin, Wu, Jingbo, Yang, Zhihui, Wang, Haiyan, Wang, Biqiong, Xiong, Kang, Lu, Yun, Fu, Shaozhi, Choi, Tak Kan, Lon, Ng Wai, Zhang, Aiping, Tang, Dongyang, Quan, Yingyao, Meng, Ya, Miao, Kai, Sun, Heng, Zhao, Ming, Bao, Jiaolin, Zhang, Lei, Xu, Xiaoling, Shi, Yanxia, Lin, Ying, Deng, Chuxia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596108/ https://www.ncbi.nlm.nih.gov/pubmed/34605222 http://dx.doi.org/10.1002/advs.202101176 |
Ejemplares similares
-
Combining CXCL10 gene therapy and radiotherapy improved therapeutic efficacy in cervical cancer HeLa cell xenograft tumor models
por: ZHAO, MING, et al.
Publicado: (2015) -
Efficient inhibition of cervical cancer by dual drugs loaded in biodegradable thermosensitive hydrogel composites
por: Xu, Shan, et al.
Publicado: (2017) -
NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation
por: Miao, Kai, et al.
Publicado: (2020) -
Expression of BRCA1 and ERCC1 as predictive clinical outcome after radiochemotherapy in patients with locoregionally moderate-advanced nasopharyngeal carcinoma
por: Xu, Shan, et al.
Publicado: (2017) -
S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy
por: Li, Jianjie, et al.
Publicado: (2022)